Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 5
1987 4
1988 6
1992 3
1993 2
1994 1
1995 4
1996 2
2000 1
2001 1
2002 5
2003 3
2004 3
2005 1
2008 1
2010 1
2011 2
2012 2
2013 3
2014 1
2015 1
2017 2
2018 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.
Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR. Hong D, et al. Among authors: blakey dc. Sci Transl Med. 2015 Nov 18;7(314):314ra185. doi: 10.1126/scitranslmed.aac5272. Sci Transl Med. 2015. PMID: 26582900 Free PMC article. Clinical Trial.
Immunotoxins.
Blakey DC, Thorpe PE. Blakey DC, et al. Bioessays. 1986 Jun;4(6):292-7. doi: 10.1002/bies.950040615. Bioessays. 1986. PMID: 3539112 No abstract available.
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.
Ross SJ, Revenko AS, Hanson LL, Ellston R, Staniszewska A, Whalley N, Pandey SK, Revill M, Rooney C, Buckett LK, Klein SK, Hudson K, Monia BP, Zinda M, Blakey DC, Lyne PD, Macleod AR. Ross SJ, et al. Among authors: blakey dc. Sci Transl Med. 2017 Jun 14;9(394):eaal5253. doi: 10.1126/scitranslmed.aal5253. Sci Transl Med. 2017. PMID: 28615361
Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.
Reebye V, Huang KW, Lin V, Jarvis S, Cutilas P, Dorman S, Ciriello S, Andrikakou P, Voutila J, Saetrom P, Mintz PJ, Reccia I, Rossi JJ, Huber H, Habib R, Kostomitsopoulos N, Blakey DC, Habib NA. Reebye V, et al. Among authors: blakey dc. Oncogene. 2018 Jun;37(24):3216-3228. doi: 10.1038/s41388-018-0126-2. Epub 2018 Mar 7. Oncogene. 2018. PMID: 29511346 Free PMC article.
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial.
Sarker D, Plummer R, Meyer T, Sodergren MH, Basu B, Chee CE, Huang KW, Palmer DH, Ma YT, Evans TRJ, Spalding DRC, Pai M, Sharma R, Pinato DJ, Spicer J, Hunter S, Kwatra V, Nicholls JP, Collin D, Nutbrown R, Glenny H, Fairbairn S, Reebye V, Voutila J, Dorman S, Andrikakou P, Lloyd P, Felstead S, Vasara J, Habib R, Wood C, Saetrom P, Huber HE, Blakey DC, Rossi JJ, Habib N. Sarker D, et al. Among authors: blakey dc. Clin Cancer Res. 2020 Aug 1;26(15):3936-3946. doi: 10.1158/1078-0432.CCR-20-0414. Epub 2020 May 1. Clin Cancer Res. 2020. PMID: 32357963 Clinical Trial.
Antibody toxin conjugates: a perspective.
Blakey DC, Wawrzynczak EJ, Wallace PM, Thorpe PE. Blakey DC, et al. Prog Allergy. 1988;45:50-90. Prog Allergy. 1988. PMID: 3064097 Review. No abstract available.
Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling.
Michaud NR, Wang Y, McEachern KA, Jordan JJ, Mazzola AM, Hernandez A, Jalla S, Chesebrough JW, Hynes MJ, Belmonte MA, Wang L, Kang JS, Jovanovic J, Laing N, Jenkins DW, Hurt E, Liang M, Frantz C, Hollingsworth RE, Simeone DM, Blakey DC, Bedian V. Michaud NR, et al. Among authors: blakey dc. Mol Cancer Ther. 2014 Feb;13(2):386-98. doi: 10.1158/1535-7163.MCT-13-0420. Epub 2013 Dec 16. Mol Cancer Ther. 2014. PMID: 24344235
56 results